Search Result

Results for "

P2X receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	P2X Receptor (114) 5-HT Receptor (5) Adiponectin Receptor (1) Angiotensin Receptor (1) Antibiotic (1) Apoptosis (8) Autophagy (3) Bacterial (1) Biochemical Assay Reagents (1) c-Myc (1) Calcium Channel (2) CaMK (1) Caspase (3) COX (2) CXCR (1) Cytochrome P450 (2) Dengue Virus (1) Drug Intermediate (1) Drug Isomer (1) Endogenous Metabolite (1) Environmental Pollutants (2) ERK (1) FAK (1) Farnesyl Transferase (1) Flavivirus (1) Fluorescent Dye (1) Gap Junction Protein (1) Glutamate Dehydrogenase (GLDH) (1) Guanylate Cyclase (1) Histamine Receptor (2) HIV (2) HSV (1) Influenza Virus (1) Interleukin Related (8) Isotope-Labeled Compounds (3) Melatonin Receptor (2) MicroRNA (1) Mitophagy (1) MMP (2) Na+/Ca2+ Exchanger (1) NF-κB (1) NOD-like Receptor (NLR) (4) NTPDase (1) Nucleoside Antimetabolite/Analog (1) P2Y Receptor (6) p38 MAPK (3) Parasite (1) PERK (3) Pregnane X Receptor (PXR) (1) Prokineticin Receptor (1) Prostaglandin Receptor (2) Pyroptosis (1) Reactive Oxygen Species (ROS) (3) Reference Standards (11) SARS-CoV (1) Sodium Channel (2) Topoisomerase (1) TRP Channel (2) Tyrosinase (1) UGT (1) α-synuclein (2)
By Research Areas:	Cancer (26) Cardiovascular Disease (13) Endocrinology (1) Infection (5) Inflammation/Immunology (48) Metabolic Disease (6) Neurological Disease (65)
Oligonucleotides:	Nucleotide Analogs (1) Adenine Nucleotide (1)

127

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: P2X Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136254

BzATP triethylammonium salt 10+ Cited Publications	P2X Receptor	Inflammation/Immunology Cancer
BzATP triethylammonium salt acts as a **P2X receptor agonist with pEC₅₀*s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively . BzATP triethylammonium salt is potent at P2X7 receptors* with EC₅₀s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively .

HY-112461A

NF449 octasodium 4 Publications Verification	P2X Receptor	Cardiovascular Disease
NF449 octasodium is a highly potent **P2X₁ receptor antagonist, with IC₅₀*s of 0.28, 0.69, and 120 nM for rP2X₁, rP2X₁₊₅, P2X₂₊₃,* respectively. NF449 octasodium is a G_sα-selective G Protein antagonist. NF449 octasodium suppresses the rate of GTP[γS] binding to G_sα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to G_s .

HY-101044

PPADS tetrasodium 5+ Cited Publications	P2X Receptor Na+/Ca2+ Exchanger	Neurological Disease
PPADS tetrasodiuma is a non-selective **P2X receptor** antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC₅₀s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC₅₀~0.9 mM) and recombinant P2Y4 (IC₅₀~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca ²⁺ exchanger in guinea pig airway smooth muscle .

HY-101588

Gefapixant 2 Publications Verification MK-7264; AF-219	P2X Receptor	Inflammation/Immunology
Gefapixant is an orally active and potent purinergic **P2X3 receptor** (P2X3R) antagonist, with IC₅₀ values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant can be used for the research of chronic cough and knee osteoarthritis .

HY-108652

α,β-Methylene-ATP trisodium 1 Publications Verification	P2X Receptor	Inflammation/Immunology
α,β-Methylene-ATP trisodium is an agonist of *P2X1* and *P2X3* receptors and can cross the blood-brain barrier. α,β-Methylene-ATP trisodium can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP trisodium also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP trisodium can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .

HY-50697

A-740003 15+ Cited Publications	P2X Receptor	Neurological Disease
A-740003 is a potent, selective and competitive **P2X7 receptor antagonist with IC₅₀** values are 18 and 40 nM for rat and human P2X7 receptors, respectively.

HY-15488

A 438079 25+ Cited Publications	P2X Receptor	Neurological Disease
A 438079 is a potent, and selective **P2X₇ receptor** antagonist with pIC₅₀ of 6.9.

HY-15488A

A 438079 hydrochloride 25+ Cited Publications	P2X Receptor	Neurological Disease
A 438079 (hydrochloride) is a potent, and selective **P2X₇ receptor** antagonist with pIC₅₀ of 6.9.

HY-109170

Eliapixant BAY 1817080	P2X Receptor	Inflammation/Immunology
Eliapixant (BAY 1817080) is a potent and selective antagonist of **P2X3 receptor, with an IC₅₀** of 8 nM. Eliapixant can be used for the research of refractory chronic cough .

HY-101588A

Gefapixant citrate 2 Publications Verification MK-7264 citrate; AF-219 citrate	P2X Receptor	Inflammation/Immunology
Gefapixant citrate is an orally active and potent purinergic **P2X3 receptor** (P2X3R) antagonist, with IC₅₀ values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant citrate can be used for the research of chronic cough and knee osteoarthritis .

HY-108669

AZ10606120 dihydrochloride 2 Publications Verification	P2X Receptor	Neurological Disease Cancer
AZ10606120 dihydrochloride is a selective, high affinity antagonist for P2X7 receptor (P2X7R) at human and rat with an IC₅₀ of about 10 nM. AZ10606120 dihydrochloride is little or no effect at other P2XR subtypes. AZ10606120 dihydrochloride has anti-depressant effects and reduces tumour growth .

HY-15568

A-317491 5 Publications Verification	P2X Receptor	Neurological Disease Inflammation/Immunology
A-317491 is a potent, selective and non-nucleotide antagonist of *P2X₃* and **P2X_2/3 receptors, with K_is of 22, 22, 9, and 92 nM for hP2X₃, rP2X₃, hP2X_2/3, and rP2X_2/3, respectively. A-317491 is highly selective (IC50*>10 μM) over other P2 receptors* and other neurotransmitter receptors, ion channels, and enzymes. A-317491 reduces inflammatory and neuropathic pain by blocking P2X₃ and P2X_2/3 receptor-mediated calcium flux .

HY-B1901

Eperisone hydrochloride (±)-Eperisone hydrochloride	P2X Receptor	Neurological Disease
Eperisone Hydrochloride ((±)-Eperisone hydrochloride) is an orally active antispastic agent with a vasodilator effect, used for the research of muscle stiffness and pain. Eperisone Hydrochloride is a potent and selectively **P2X7 receptor antagonist, also shows antagonism for human P2X3**. Eperisone Hydrochloride works by relaxing both skeletal muscles and vascularsmooth muscles, demonstrating a variety of effects such as reduction ofmyotonia, improvement of circulationand and suppression of the pain reflex .

HY-D0976

NF279 1 Publications Verification	P2X Receptor HIV NTPDase CXCR	Infection
NF279 is a selective *P2X1* receptor antagonist and NTPDase inhibitor, with a P2X1 IC₅₀ value of 19 nM. NF279 suppresses GABA-evoked currents, reduces ATP-excited respiratory activity, alters hypoglossal nerve burst parameters, and blocks CXCR4, CCR5, CXCR3, and CXCR7-mediated calcium responses. NF279 arrests HIV-1 fusion downstream of CD4 binding, inhibits R5- and X4-tropic HIV-1 strains. NF279 can be used for the research of HIV-1 infection .

HY-14483

AF-353 1 Publications Verification Ro-4	P2X Receptor	Cancer
AF-353 (Ro-4) is a potent, selective and orally bioavailable **P2X3/P2X2/3 receptor antagonist, with a pIC₅₀** of 8.0 for both human and rat P2X3, and with a pIC₅₀ of 7.3 for human P2X2/3 .

HY-108667

TNP-ATP triethylammonium	P2X Receptor Interleukin Related Fluorescent Dye	Neurological Disease
TNP-ATP triethylammonium is a *P2X* receptor antagonist with an IC₅₀ of 0.010 μM for *P2X₃* and an IC₅₀ of 0.062 μM for *P2X_2/3. TNP-ATP triethylammonium acts as an inhibitor of CheA* autophosphorylation, with a K_i of 0.7 µM. TNP-ATP triethylammonium blocks the functional activation of *P2X_1-7* receptors. TNP-ATP triethylammonium attenuates hypoxia-induced IL-1β expression and release. TNP-ATP triethylammonium alleviates visceral pain, and improves hypoxia-induced cognitive impairment, insufficient myelination and neuroinflammation. Binding of TNP-ATP triethylammonium to CheA enhances the fluorescence of the TNP group. TNP-ATP triethylammonium can be used in studies related to visceral pain. NP-ATP triethylammonium can be used in studies related to hypoxia-induced insufficient myelination and cognitive decline .

HY-N5025

Bullatine A	P2X Receptor Apoptosis ERK p38 MAPK c-Myc NF-κB Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology Cancer
Bullatine A, a diterpenoid alkaloid, is a potent *P2X7* antagonist. Bullatine A possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A inhibits ATP-induced BV-2 cell death/apoptosis and **P2X receptor**-mediated inflammatory responses. Bullatine A suppresses glioma cell growth by targeting SIRT6. Bullatine A specifically attenuates pain hypersensitivity in rats. Bullatine A attenuates LPS (HY-D1056)-induced systemic inflammatory response by inhibiting the ROS/JNK/NF-κB pathway in mice. Bullatine A improves despair behavior in Chronic chronic social defeat stress (CSDS) mice. Bullatine A can be used for the study of inflammation, glioblastoma (GBM) and depression .

HY-100483

A-804598 3 Publications Verification	P2X Receptor	Neurological Disease Cancer
A-804598 is a BBB penetrant, competitive and selective *P2X7* receptor antagonist with IC₅₀s of 9 nM, 10 nM and 11 nM for mouse, rat and human *P2X7* receptors, respectively .

HY-117508

JNJ-54175446	P2X Receptor	Neurological Disease
JNJ-54175446 is a potent and selective brain penetrant **P2X7 receptor antagonist, with pIC₅₀*s of 8.46 and 8.81 for hP2X7 receptor* and rP2X7 receptor, respectively.

HY-N1478

Gardenoside 2 Publications Verification	P2X Receptor Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology
Gardenoside is an orally active natural compound found in Gardenia fruits. Gardenoside reliefs chronic constriction injury (CCI)-induced neuropathic pain by regulating the *P2X3* and *P2X7* receptors. Gardenoside has an inhibitory effect on free fatty acids (FFA)-induced cellular steatosis. Gardenoside reduces reactive oxygen species (ROS). Gardenoside can be used for anti-inflammatory, antinociceptive and hepatoprotective study .

HY-123205

Oxatomide KW-4354	Histamine Receptor P2X Receptor 5-HT Receptor Apoptosis PERK p38 MAPK COX	Inflammation/Immunology
Oxatomide (KW-4354) is an orally active dual antagonist of the H1-histamine receptor and the **P2X7 receptor, as well as an inhibitor of serotonin**. Oxatomide possesses antihistaminic, antiallergic and anti-inflammatory activities. Oxatomide can be used in the research of allergic diseases .

HY-137451

Sivopixant 1 Publications Verification S-600918	P2X Receptor	Neurological Disease
Sivopixant (S-600918) is a potent and selective **P2X3 receptor** antagonist (P2X3 IC₅₀=4.2 nM; P2X2/3 IC₅₀=1100 nM). Sivopixant shows strong analgesic effect .

HY-134440A

α,β-Methylene-ATP	P2X Receptor	Inflammation/Immunology
α,β-Methylene-ATP is an agonist of *P2X1* and *P2X3* receptors and can cross the blood-brain barrier. α,β-Methylene-ATP can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .

HY-13954

A 839977 1 Publications Verification	P2X Receptor	Neurological Disease Inflammation/Immunology
A 839977 is a *P2X7* selective antagonist; it blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC₅₀ values are 20 nM, 42 nM and 150 nM respectively) and reduces inflammatory and neuropathic pain in animal models; the antihyperalgesic effects of P2X7 receptor blockade are mediated by blocking the release of IL-1beta .

HY-112461

NF449	P2X Receptor	Cardiovascular Disease
NF449 is a highly potent **P2X₁ receptor antagonist, with IC₅₀*s of 0.28, 0.69, and 120 nM for rP2X₁, rP2X₁₊₅, P2X₂₊₃,* respectively. NF449 is a G_sα-selective G Protein antagonist. NF449 suppresses the rate of GTP[γS] binding to G_sα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to G_s .

HY-134807

Indophagolin	P2X Receptor 5-HT Receptor Autophagy	Cancer
Indophagolin is a potent, indoline-containing autophagy inhibitor (IC₅₀=140 nM). Indophagolin antagonizes the purinergic receptor *P2X₄* as well as P2X₁ and P2X₃ with IC₅₀s of 2.71, 2.40 and 3.49 μM, respectively. Indophagolin also antagonizes the G_q-protein-coupled P2Y₄, P2Y₆, and P2Y₁₁ receptors (IC₅₀s =3.4~15.4 μM). Indophagolin has a strong antagonistic effect on serotonin receptor 5-HT₆ (IC₅₀=1.0 μM) and a moderate effect on receptors 5-HT_1B, 5-HT_2B, 5-HT_4e, and 5-HT₇ .

HY-110237

BX430	P2X Receptor Calcium Channel	Cardiovascular Disease
BX430 is a potent and selective noncompetitive allosteric *human P2X4 receptor* channels antagonist with an IC₅₀** of 0.54 μM. BX430 has species specificity. BX430 is used for chronic pain and cardiovascular disease.

HY-131502

Taspine	P2X Receptor	Inflammation/Immunology
Taspine is a natural product with anti-inflammatory activity. Taspine suppresses *P2X4* receptor activity via PI3K inhibition. Taspine inhibits pro-inflammatory signalling via inhibition of P2X4 receptors in macrophage .

HY-108960

PPADS	P2X Receptor Interleukin Related	Neurological Disease
PPADS is a *P2X* receptor (P2X *Receptor) antagonist and a reversible competitive antagonist of NAADP* receptors, with IC₅₀ values of 68 nM (P2X1) and 214 nM (P2X3), respectively. PPADS alleviates pain-related behaviors in the central and peripheral nervous systems of mice after peripheral neuropathy, inhibits the overproduction of IL-1β, IL-6, iNOS and nNOS, and suppresses the hydrolytic activity of extracellular ATPase. PPADS blocks ATP-mediated inward currents on recombinant rat *P2X₁* and *P2X₃* receptors, and inhibits purinergic nerve stimulation-induced contraction of rabbit bladder detrusor muscle. PPADS is applicable to research related to neuropathic pain .

HY-135976

P2X3 antagonist 34	P2X Receptor	Neurological Disease Inflammation/Immunology
P2X3 antagonist 34 is a potent, selective and orally active **P2X3 homotrimeric receptor antagonist with IC₅₀*s of 25 nM, 92 nM and 126 nM for human P2X3, rat P2X3* and guinea pig P2X3 receptors, respectively. P2X3 antagonist 34 is less active against human, rat and guinea pig P2X2/3 heterotrimeric receptors. P2X3 antagonist 34 has strong anti-tussive effect .

HY-108676

NF023 hexasodium 1 Publications Verification	P2X Receptor	Neurological Disease
NF023 hexasodium is a selective and competitive **P2X₁ receptor antagonist, with IC₅₀** values of 0.21 μM, 28.9 μM, > 50 μM and > 100 μM for human P2X₁, P2X₃, P2X₂, and P2X₄-mediated responses respectively .

HY-101308A

MRS2179 tetrasodium hydrate 2 Publications Verification	P2Y Receptor	Cardiovascular Disease
MRS2179 tetrasodium hydrate is a competitive P2Y1 receptor antagonist, with a K_b of 102 nM and a pA₂ of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium hydrate inhibits platelet aggregation .

HY-15487

CE-224535 PF-04905428	P2X Receptor	Neurological Disease
CE-224535 is a selective **P2X₇ receptor** antagonist.

HY-137325A

2-Chloro-ATP sodium	Calcium Channel	Metabolic Disease
2-Chloro-ATP sodium (2-Chloro ATP) is an adenine nucleotide and an analog of ATP. It is an antagonist of the purinergic P2Y1 receptor and inhibits intracellular calcium mobilization induced by ADP (HY-W010918) in Jurkat cells expressing the human receptor (Ki=2.3 μM). 2-Chloro-ATP sodium is an agonist of the purinergic P2X receptor and induces inward currents in HEK293 cells expressing human bladder smooth muscle or rat PC12 forms of the receptor (EC50=0.5 and 2.5 μM). 2-Chloro-ATP sodium induces relaxation of precontracted guinea pig cecal strips in a concentration-dependent manner. 2-Chloro-ATP sodium has been used to study the substrate specificity of cyclic nucleotide-dependent protein kinases such as protein kinase A (PKA) and PKG.

HY-150059

P2X7 receptor antagonist-2	P2X Receptor	Neurological Disease Inflammation/Immunology
P2X7 receptor antagonist-2 is a potent **P2X7 receptor antagonist with a pIC₅₀** value of 6.5-7.5. P2X7 receptor antagonist-2 has efficacy of combating neuroinflammation .

HY-15568A

A-317491 sodium salt hydrate 5 Publications Verification	P2X Receptor	Neurological Disease Inflammation/Immunology
A-317491 sodium salt hydrate is a potent, selective and non-nucleotide antagonist of *P2X₃* and **P2X_2/3 receptors, with K_is of 22, 22, 9, and 92 nM for hP2X₃, rP2X₃, hP2X_2/3, and rP2X_2/3, respectively. A-317491 sodium salt hydrate is highly selective (IC50*>10 μM) over other P2 receptors* and other neurotransmitter receptors, ion channels, and enzymes. A-317491 sodium salt hydrate reduces inflammatory and neuropathic pain by blocking P2X₃ and P2X_2/3 receptor-mediated calcium flux .

HY-18745

BzATP triethylammonium Benzoylbenzoyl-ATP triethylammonium	P2X Receptor	Inflammation/Immunology Cancer
BzATP triethylammonium acts as a **P2X receptor agonist with pEC₅₀*s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively . BzATP triethylammonium is potent at P2X7 receptors* with EC₅₀s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively .

HY-109173

Filapixant BAY 1902607	P2X Receptor Cytochrome P450	Inflammation/Immunology
Filapixant (BAY 1902607) is an orally active and selective *P2X3* receptor antagonist. Filapixant is applicable to the research of refractory chronic cough .

HY-16322

Minodronic acid 1 Publications Verification YM-529	P2X Receptor Apoptosis Farnesyl Transferase	Metabolic Disease Cancer
Minodronic acid (YM-529) is an FPP synthase inhibitor with an IC₅₀ of 3 nM, and also an antagonist of **P2X2/3 receptors with an IC₅₀ of 62.7 μM. Minodronic acid induces tumor cell apoptosis** and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer .

HY-16322A

Minodronic acid hydrate 1 Publications Verification YM-529 hydrate	P2X Receptor Apoptosis	Metabolic Disease Cancer
Minodronic acid (YM-529) hydrate is an FPP synthase inhibitor with an IC₅₀ of 3 nM, and also an antagonist of **P2X2/3 receptors with an IC₅₀ of 62.7 μM. Minodronic acid hydrate induces tumor cell apoptosis** and inhibits cell growth. Minodronic acid hydrate also suppresses bone resorption. Minodronic acid hydrate can be used in research related to osteoporosis and cancer .

HY-B1901R

Eperisone hydrochloride (Standard) (±)-Eperisone hydrochloride (Standard)	P2X Receptor Reference Standards	Neurological Disease
Eperisone (hydrochloride) (Standard) is the analytical standard of Eperisone (hydrochloride). This product is intended for research and analytical applications. Eperisone Hydrochloride ((±)-Eperisone hydrochloride) is an orally active antispastic agent with a vasodilator effect, used for the research of muscle stiffness and pain. Eperisone Hydrochloride is a potent and selectively P2X7 receptor antagonist, also shows antagonism for human P2X3. Eperisone Hydrochloride works by relaxing both skeletal muscles and vascularsmooth muscles, demonstrating a variety of effects such as reduction ofmyotonia, improvement of circulationand and suppression of the pain reflex .

HY-160645

P2X4 antagonist-1	P2X Receptor	Neurological Disease Endocrinology Cancer
P2X4 antagonist-1 is a **P2X4 receptor antagonist with an IC₅₀** of 15 nM. P2X4 antagonist-1 inhibits ATP (HY-B2176)-induced calcium influx. P2X4 antagonist-1 can be used for the research of pain syndromes, endometriosis, cancer .

HY-19978

RO-3	P2X Receptor	Neurological Disease
RO-3 is a potent, and orally active *P2X₃* and *P2X_2/3* antagonist with pIC₅₀s of 5.9 and 7.0 for human homomultimeric P2X₃ and heteromultimeric P2X_2/3 receptors, respectively. RO-3 shows selectivity for P2X₃ and P2X_2/3 over all other functional homomultimeric P2X receptors (IC₅₀ >10 μM at P2X_1,2,4,5,7) .

HY-19888

GSK-1482160	P2X Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
GSK-1482160 is an orally active and blood-brain barrier penetrant P2X7 receptor (P2X7R) negative allosteric modulator with pIC₅₀s of 8.5 (human) and 6.5 (rat). GSK-1482160 reduces the efficacy of ATP at the P2X7 receptor without affecting its affinity, thereby inhibiting the release of IL-1β. GSK-1482160 is an effective radioligand and can be labeled with radioactive isotopes like 11C or 18F to image P2X7R. GSK-1482160 can be used for the studies of chronic joint pain and chronic constriction injury (CCI) .

HY-145466

EVT-401	P2X Receptor	Neurological Disease
EVT-401 (P2X7 receptor antagonist-1) is a purinergic **P2X7 receptor** antagonist. EVT-401 has efficacy of combating neuroinflammation .

HY-134440

α,β-Methylene-ATP dilithium	P2X Receptor	Inflammation/Immunology
α,β-Methylene-ATP dilithium is an agonist of *P2X1* and *P2X3* receptors and can cross the blood-brain barrier. α,β-Methylene-ATP dilithium can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP dilithium also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP dilithium can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .

HY-134262

8-Bromo-ATP 8-Bromoadenosine 5'-triphosphate; 8-Br-ATP	P2X Receptor	Cancer
8-Bromo-ATP (8-Bromoadenosine 5'-triphosphate), an ATP analogue, is a purinergic **P2X receptor agonist. 8-Bromo-ATP shows cytotoxic to multiple myeloma cells with an IC₅₀** of 23.1 μM .

HY-101308

MRS2179 tetrasodium	P2Y Receptor	Cardiovascular Disease
MRS2179 tetrasodium is a competitive P2Y1 receptor antagonist, with a K_b of 102 nM and a pA₂ of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium inhibits platelet aggregation .

HY-101228

PSB-12054	P2X Receptor	Neurological Disease
PSB-12054 is a selective *P2X4* antagonist with an IC₅₀ of 0.189 μM at human P2X4 receptors. PSB-12054 can be used in the research of neuropathic pain and neurodegenerative diseases .

HY-15469

GW791343 dihydrochloride 1 Publications Verification	P2X Receptor	Neurological Disease
GW791343 dihydrochloride is a potent human *P2X7* receptor negative allosteric modulator (exhibits species-specific activity), produces a non-competitive antagonist effect on human *P2X7* receptor, with a pIC₅₀ of 6.9-7.2. GW791343 dihydrochloride can enhance ATP rhythm. GW791343 dihydrochloride can be used in study of neurological disease .

Cat. No.	Product Name	Type

HY-D0914

Fast Green FCF

FD&C Green No. 3; Food green 3; C.I. 42053

Fluorescent Dyes

Fast Green FCF is a sea green triarylmethane food dye, with absorption maximum ranging from 622 to 626 nm. Fast Green FCF inhibits α-synuclein aggregation, as well as Aβ and P2X4 receptor, and TLR4/Myd88/NF-κB. Fast Green FCF is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

HY-D0914A

Fast green FCF free acid

Fluorescent Dyes

Fast green FCF free acid is a dye that is acid-resistant. Fast Green FCF free acid inhibits α-synuclein aggregation, as well as Aβ, P2X4 receptor and TLR4/Myd88/NF-κB. Fast Green FCF free acid is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF free acid improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

Cat. No.	Product Name	Target	Research Area

HY-P1137

10Panx 1 Publications Verification	Gap Junction Protein	Others
10Panx is a competitive inhibitor of selective Pannexin 1 (PANX1) channels. 10Panx blocks the opening of PANX1 channels, inhibits ATP release and downstream **P2X7 receptor**-mediated signaling pathways, thereby reducing cell death and inflammatory responses. 10Panx can be used in the study of diseases such as neuropathic pain, inflammatory bowel disease, and Clostridioides difficile infection. 10Panx can effectively reduce mechanical hyperalgesia and enhanced C-reflexes, and inhibit the expression of pro-inflammatory factors such as IL-6[1][2][3].

HY-P1330

Purotoxin 1	P2X Receptor	Inflammation/Immunology
Purotoxin 1 is a **P2X3 receptor** inhibitor. Purotoxin 1 shows antinociceptive properties in animal models of inflammatory pain. Purotoxin 1 can be isolated from the venom of the wolf spider Geolycosa sp .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15310

Ivermectin 45+ Cited Publications MK-933; CD-5024; K-237	Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Antiviral Anti-parasitic Disease Research Disease Research Fields Source Classification Cancer	Environmental Pollutants Antibiotic Mitophagy Bacterial Parasite Autophagy Flavivirus HSV HIV SARS-CoV Dengue Virus
Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of *P2X₄* and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 .

HY-N5025

Bullatine A	Alkaloids Piperidine Alkaloids Classification of Application Fields Ranunculaceae Aconitum carmichaeli Debx. Plants Inflammation/Immunology Disease Research Fields Source Classification	P2X Receptor Apoptosis ERK p38 MAPK c-Myc NF-κB Reactive Oxygen Species (ROS)
Bullatine A, a diterpenoid alkaloid, is a potent *P2X7* antagonist. Bullatine A possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A inhibits ATP-induced BV-2 cell death/apoptosis and **P2X receptor**-mediated inflammatory responses. Bullatine A suppresses glioma cell growth by targeting SIRT6. Bullatine A specifically attenuates pain hypersensitivity in rats. Bullatine A attenuates LPS (HY-D1056)-induced systemic inflammatory response by inhibiting the ROS/JNK/NF-κB pathway in mice. Bullatine A improves despair behavior in Chronic chronic social defeat stress (CSDS) mice. Bullatine A can be used for the study of inflammation, glioblastoma (GBM) and depression .

HY-N1478

Gardenoside 2 Publications Verification	Iridoids Terpenoids Rubiaceae Plants Gardenia jasminoides Ellis Source Classification	P2X Receptor Reactive Oxygen Species (ROS)
Gardenoside is an orally active natural compound found in Gardenia fruits. Gardenoside reliefs chronic constriction injury (CCI)-induced neuropathic pain by regulating the *P2X3* and *P2X7* receptors. Gardenoside has an inhibitory effect on free fatty acids (FFA)-induced cellular steatosis. Gardenoside reduces reactive oxygen species (ROS). Gardenoside can be used for anti-inflammatory, antinociceptive and hepatoprotective study .

HY-N9182

Zeaxanthin dipalmitate Physalien	Structural Classification Classification of Application Fields Terpenoids Diterpenoids Solanaceae Plants Lycium chinense Miller Inflammation/Immunology Disease Research Fields Source Classification	Adiponectin Receptor P2X Receptor Autophagy
Zeaxanthin dipalmitate (Physalien) is a wolfberry-derived carotenoid, has anti-inflammatory and anti-oxidative stress effects. Zeaxanthin dipalmitate directly interact with **p2X7 receptor (K_d=81.2 nM) and adiponectin receptor 1 (AdipoR1; K_d=533 nM) in a positive dose-dependent manner. Zeaxanthin dipalmitate restores mitochondrial autophagy** functions suppressed by ethanol intoxication. Zeaxanthin dipalmitate can be used in the research of alcoholic fatty liver disease (AFLD) and retinitis pigmentosa (RP) .

HY-N7740

Adenosine 2',5'-diphosphate sodium	Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	P2Y Receptor Endogenous Metabolite
Adenosine 2',5'-diphosphate sodium is a competitive P2Y1 antagonist. Adenosine 2',5'-diphosphate sodium exhibits non-selective antagonism at recombinant and human platelet *P2X1* receptors .

HY-N1478R

Gardenoside (Standard)	Structural Classification Iridoids Terpenoids Rubiaceae Plants Gardenia jasminoides Ellis Source Classification	Reference Standards P2X Receptor Reactive Oxygen Species (ROS)
Gardenoside is an orally active natural compound found in Gardenia fruits. Gardenoside reliefs chronic constriction injury (CCI)-induced neuropathic pain by regulating the P2X3 and P2X7 receptors. Gardenoside has an inhibitory effect on free fatty acids (FFA)-induced cellular steatosis. Gardenoside reduces reactive oxygen species (ROS). Gardenoside can be used for anti-inflammatory, antinociceptive and hepatoprotective study .

Cat. No.	Product Name	Chemical Structure

HY-151546S

MRS4596-d4
MRS4596-d₄ is the deuterium labeled MRS4596 (HY-151546). MRS4596 is a potent and selective **P2X4 receptor antagonist with an IC₅₀** value of 1.38 μM for human P2X4 receptor. MRS4596 has neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4596 can be used in research of ischemic stroke .

HY-151547S

MRS4719-d3

MRS4719-d₃ is the deuterium labeled MRS4719 (HY-151547). MRS4719 is a potent P2X4 receptor antagonist with an IC₅₀ value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca ²⁺]_i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke .

HY-16322S

Minodronic acid-d4

Minodronic acid-d₄ (YM-529-d₄) is deuterium labeled Minodronic acid (HY-16322). Minodronic acid (YM-529) is an FPP synthase inhibitor with an IC₅₀ of 3 nM, and also an antagonist of P2X2/3 receptors with an IC₅₀ of 62.7 μM. Minodronic acid induces tumor cell apoptosis and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer .

Cat. No.	Product Name		Classification

HY-113273A

Diadenosine pentaphosphate pentasodium		Nucleotide Analogs Adenine Nucleotide
Diadenosine pentaphosphate pentasodium is an agonist and negative modulator of the *P2X1* receptor, an endogenous vasoactive purine dinucleotide that can be isolated from platelets. Diadenosine pentaphosphate pentasodium mediates negative regulation of dendrite growth and number by activating homologous and heterologous **P2X1 receptors, which triggers a transient and moderate increase in intracellular calcium levels within dendritic growth cones. Diadenosine pentaphosphate pentasodium is widely present in secretory vesicles such as platelets, chromaffin cells and brain synaptosomes, and exhibits selective activity on dendrite growth of cultured hippocampal neurons, inhibiting only dendrite growth without affecting axon growth. Diadenosine pentaphosphate pentasodium has a weaker ability to compete with RcCHAD** for binding to polyP than short-chain polyPs .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

P2X receptors

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products